Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-05-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiapatients mustheartfailuremarrow
  Phrases that lowered it: patients wholenalidomidesmallaminotransferasewith history
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 34.6% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 7.3% (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.7% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 55 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 15 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 41333 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT00602836 · started 2008 · scored riskier than 57% of active trials completed
• Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma NCT01076543 · started 2010 · scored riskier than 36% of active trials completed
• Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL NCT01703364 · started 2012 · scored riskier than 93% of active trials completed
• A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy NCT01556776 · started 2012 · scored riskier than 83% of active trials completed
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) NCT00536341 · started 2008 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.